ETF Managers Group, LLC Vir Biotechnology, Inc. Transaction History

ETF Managers Group, LLC

$2.78 Billion
Q1 2023

A detailed history of ETF Managers Group, LLC transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, ETF Managers Group, LLC holds 34,187 shares of VIR stock, worth $257,428. This represents 0.03% of its overall portfolio holdings.

Number of Shares

34,187

Previous 33,188 3.01%

Holding current value

$257,428

Previous $839,000 5.24%

% of portfolio

0.03%

Previous 0.04%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 17, 2023	BUY	$22.26 - $30.85 $22,237 - $30,819	999 Added 3.01%	34,187 $795,000
Q4 2022 Mar 23, 2023	SELL	$19.96 - $28.22 $816,124 - $1.15 Million	-40,888 Reduced 55.2%	33,188 $839,000
Q3 2022 Nov 14, 2022	BUY	$18.26 - $31.1 $612,257 - $1.04 Million	33,530 Added 82.7%	74,076 $1.43 Million
Q2 2022 Aug 15, 2022	BUY	$19.08 - $26.7 $7,899 - $11,053	414 Added 1.03%	40,546 $1.06 Million
Q1 2022 May 13, 2022	BUY	$21.19 - $40.01 $12,205 - $23,045	576 Added 1.46%	40,132 $1.04 Million
Q4 2021 Feb 14, 2022	SELL	$30.97 - $54.03 $251,940 - $439,534	-8,135 Reduced 17.06%	39,556 $1.61 Million
Q3 2021 Nov 15, 2021	BUY	$34.9 - $54.54 $325,686 - $508,967	9,332 Added 24.33%	47,691 $2.06 Million
Q2 2021 Aug 16, 2021	SELL	$38.75 - $51.0 $30,922 - $40,698	-798 Reduced 2.04%	38,359 $1.79 Million
Q1 2021 May 17, 2021	SELL	$26.34 - $83.07 $600,657 - $1.89 Million	-22,804 Reduced 36.8%	39,157 $1.87 Million
Q4 2020 Feb 16, 2021	SELL	$25.51 - $43.38 $174,666 - $297,022	-6,847 Reduced 9.95%	61,961 $1.75 Million
Q3 2020 Nov 16, 2020	BUY	$28.28 - $53.6 $1.39 Million - $2.63 Million	49,113 Added 249.37%	68,808 $2.6 Million
Q2 2020 Aug 14, 2020	BUY	$27.89 - $47.86 $549,293 - $942,602	19,695 New	19,695 $715,000

Others Institutions Holding VIR

# of Institutions

233

Shares Held

87.6M

Call Options Held

231K

Put Options Held

132K

View Full List

About Vir Biotechnology, Inc.

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $999M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

More about VIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of ETF Managers Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on ETF Managers Group, LLC with notifications on news.

Account

ETF Managers Group, LLC Vir Biotechnology, Inc. Transaction History